Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
RavassaSZudaireADezJ
Incretin action of GIP is dramatically reduced in the presence of diabetes, as demonstrated by the evidence that glucose-dependent insulin secretion is not potentiated by GIP administration in subjects with diabetes [33, 34]
It increases the likelihood of severe gastrointestinal distress and hypoglycemia without providing any scientifically proven benefit to your weight loss journey
PlexusDx recommends discussing this approach with your physician and exploring whether tirzepatide monotherapy or PlexusDx's dual-compound options better suit your needs
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Comparator-Controlled, Parallel-Group, Phase 2 Trial
